RELATED STORY | FDA panel rejects the use of psychedelic drug MDMA to treat patients with PTSD Lykos said the issues FDA raised in what's called a complete response letter echoed the concerns ...

The Food and Drug Administration (FDA) panel voted 10-1 against endorsing the safety of MDMA in treating PTSD, and 9-2 against ... be used as a rationale to reject the treatment.

A first-of-a-kind proposal to begin using the mind-altering drug MDMA as a treatment for PTSD was roundly criticized Tuesday — a potentially major setback to psychedelic advocates who hope to ...

The FDA has denied Lykos Therapeutics' marketing application for its post-traumatic stress disorder (PTSD) therapy based on MDMA, also known as ecstasy, in a setback for the emerging psychedelic ...

the U.S. Food and Drug Administration (FDA) made the decision not to approve MDMA-assisted therapy for post-traumatic stress disorder. This decision comes just months after advisors to the agency ...

The Texas House and Senate have approved a new state fund for research into ibogaine, which has been used by veterans to ...

Multidisciplinary Association for Psychedelic Studies (MAPS), the FDA has agreed study designs for two phase 3 studies assessing MDMA-assisted psychotherapy for patients with severe PTSD.

Kaya Holdings Advocates For Psilocybin As FDA Rejects MDMA For PTSD Treatment Kaya Holdings criticizes the FDA's rejection of MDMA therapy for PTSD, proposing psilocybin as a viable alternative ...

or administering), the FDA labeled MDMA-assisted psychotherapy a “beakthrough therapy” for PTSD in 2017. (Schedule I drugs are substances considered to have “no currently accepted medical ...

Although that seems promising, the FDA’s decision last year to reject public use of MDMA-assisted therapy for PTSD created a major setback for researchers and patients, according to experts.